Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aidan Fry

With over 20 years of experience of reporting on the global pharmaceutical industry, Aidan focuses in his role as editor of Generics bulletin particularly on commercial, regulatory and legal issues affecting the generic, biosimilar, value-added and OTC medicines industries. This includes in-depth analyses of corporate strategy, legislative changes, legal precedents and product perspectives. He regularly interviews leading industry executives and moderates prestigious events. Aidan also oversees the Global Generics & Biosimilars Awards. Aidan speaks fluent German and has a particular affection for maps.
Set Alert for Articles By Aidan Fry

Latest From Aidan Fry

Apotex Is Blocked On Canadian Abiraterone

Apotex has failed to convince a Canadian federal court that a patent protecting Janssen’s Zytiga abiraterone brand until August 2027 is invalid and not infringed by its proposed generic version of the prostate-cancer treatment.

Intellectual Property Canada

Sandoz Is Stalled On Swiss Pemetrexed

Sandoz’ unsuccessful attempts to show a lack of inventive step in a Swiss vitamin regimen patent leave Lilly’s Alimta pemetrexed brand protected until 2021.

Intellectual Property Switzerland

Pfenex Expects To Be Alone With Teriparatide

Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.

Launches United States

Mylan Reforms As It Prepares To Become Viatris

Mylan is pushing ahead with reforms that include wide-ranging product rationalization in the US, refocusing its commercial resources and cutting development and manufacturing costs. These reforms are intended to run prior to and concurrently with the group’s merger with Pfizer’s Upjohn unit to form Viatris.

Business Strategies Manufacturing

Czech Republic's Zentiva Snaps Up Alvogen’s CEE Operations

Acquiring Alvogen’s operations in central and eastern Europe will strengthen private equity-backed Zentiva’s presence in both the OTC and generics markets.
Czech Republic Europe

Mylan Prepares For US Trastuzumab Entry

Mylan is preparing to launch a trastuzumab biosimilar in the US, while progress of developing bevacizumab and aflibercept biosimilars continues. Insulin aspart and glargine are also in Mylan’s pipeline.

Biosimilars Launches
See All
UsernamePublicRestriction

Register